Search by Drug Name or NDC
NDC 72786-0102-03 OXBRYTA 300 mg/1 Details
OXBRYTA 300 mg/1
OXBRYTA is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc.. The primary component is VOXELOTOR.
Product Information
| NDC | 72786-0102 |
|---|---|
| Product ID | 72786-102_e27a3e07-438e-49d3-aae3-095e9379c7b4 |
| Associated GPIs | |
| GCN Sequence Number | 084244 |
| GCN Sequence Number Description | voxelotor TABLET 300 MG ORAL |
| HIC3 | N1H |
| HIC3 Description | SICKLE CELL ANEMIA AGENTS |
| GCN | 53456 |
| HICL Sequence Number | 046225 |
| HICL Sequence Number Description | VOXELOTOR |
| Brand/Generic | Brand |
| Proprietary Name | OXBRYTA |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Voxelotor |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 300 |
| Active Ingredient Units | mg/1 |
| Substance Name | VOXELOTOR |
| Labeler Name | Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc. |
| Pharmaceutical Class | Cytochrome P450 3A4 Inhibitors [MoA], Hemoglobin S Polymerization Inhibitor [EPC], Hemoglobin S Polymerization Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA213137 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 72786-0102-03 (72786010203)
| NDC Package Code | 72786-102-03 |
|---|---|
| Billing NDC | 72786010203 |
| Package | 90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72786-102-03) |
| Marketing Start Date | 2022-10-14 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |